Gamma Delta T Cells
Vγ9Vδ2 (Vgamma9 Vdelta2) T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the clinic
lavatherapeutics.comCrawled Nov 11, 2026
Vγ9Vδ2 (Vgamma9 Vdelta2) T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the clinic
LAVA’s bispecific gamma delta (𝛾𝛿) T cell engagers (bsTCEs) directly induce potent killing of tumor cells
LAVA-051 is a humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.
A bispecific single domain antibody boosts autologous Vγ9Vδ2-T cell responses towards CD1d in chronic lymphocytic leukemia
Bispecific antibodies are molecules designed to recognize two distinct epitopes or antigens.
2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation Brojil, et al.
LAVA-051 planned to enter first-in-human clinicalphase 1/2a study in patients with CLL, MM or AMLwho are refractory to prior therapy
LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform.
Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation.
Lava Therapeutics B.V., a biotech company pioneering bispecific gamma-delta T cell engagers for cancer, today announced the appointment of Benjamin Winograd, M.D., Ph.D., as the company’s Chief Medical Officer.
LAVA Therapeutics announced Stephen Hurly, its CEO, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.
LAVA Therapeutics, Amsterdam UMC, and the Monash Biomedicine Discovery Institute published research in *Nature Cancer* on a bispecific antibody targeting CD1d and the NKT T-cell receptor for cancer treatment.
Lava Therapeutics Board of Directors
Dieter Kabelitz was a full professor at the University of Kiel and Director of the Institute of Immunology from 1999 to 2018, where he continues to work as a senior research group leader.
Dr. James Patrick (Jim) Allison is an American immunologist and a 2018 Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.
Lava Therapeutics Management Team
Madhav V. Dhodapkar, MBBS, is the Anise McDaniel Brock Chair and Georgia Research Alliance Eminent Scholar in Cancer Innovation and Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Andrea van Elsas, Ph.D., joined LAVA Therapeutics as chair of the scientific advisory board in April 2018. He is a venture partner with Third Rock Ventures and chief scientific officer at Abata Therapeutics.
Lava is focused on applying expertise in gamma-delta T cell engagers (TCEs) to transform cancer therapy.
LAVA Therapeutics has offices in Utrecht and Philadelphia.
Innovation in engaging gamma-delta T cells to potently and precisely fight cancer